

INTERNATIONAL APPLICA

PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>4</sup> :

C12N 5/00 // C12P 21/00

A1

(11) International Publication Number:

WO 86/ 01530

(43) International Publication Date:

13 March 1986 (13.03.86)

(21) International Application Number: PCT/DK85/00083

(22) International Filing Date: 23 August 1985 (23.08.85)

(31) Priority Application Number: 4029/84

(32) Priority Date: 23 August 1984 (23.08.84)

(33) Priority Country: DK

(71) Applicant (for all designated States except US): NOR-DISK GENTOFTE A/S [DK/DK]; Niels Steensensvej 1, DK-2820 Gentofte (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only) : NIELSEN, Jens, Høiriis [DK/DK]; I.E. Ohlsensgade 14, IV, DK-2100 København Ø (DK).

(74) Agent: HOFMAN-BANG &amp; BOUTARD A/S; Adelgade 15, DK-1304 København K (DK).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US.

Published

*With international search report.**In English translation (filed in Danish).*

INF. C12P21/02 B1

(54) Title: A PROCESS FOR PROLIFERATION OF WHOLLY OR PARTIALLY DIFFERENTIATED BETA-CELLS

(57) Abstract

A process for proliferation of wholly or partially differentiated beta-cells comprises depositing islets or islet cultures from the pancreases of human or animal origin as monolayers on a solid substrate and keeping them in contact with a glucose-containing nutrient medium containing 1/2 - 7% human serum and 1 - 1000 ng growth hormone per ml nutrient medium. Cultivation of the beta-cells under such conditions provides continuous or long-term proliferation of the cells and a simultaneous strong increase in the insulin production.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

A process for proliferation of wholly or partially  
differentiated beta-cells  
-----

The present invention relates to a process of the type defined in the introductory portion of claim 1 for proliferation of wholly or partially differentiated beta-cells.

5

The type I diabetes mellitus disease is usually accompanied by progressive destruction of the insulin producing so-called beta-cells in the islets of Langerhans. Patients suffering from this disease are  
10 normally treated with daily injections of insulin recovered from the pancreas from animals, such as beef or pig, or produced by engineering. However, this mode of treatment is still incomplete, and complications at the advanced stages of the disease result in a high mortality  
15 rate among diabetics.

A considerably better regulation of the glucose content of the blood may be obtained by transplantation of tissue from pancreas or isolated islets of Langerhans,  
20 which is believed to reduce the risk of the mentioned complications considerably. However, for this treatment to be used on a larger scale, it is required that sufficient amounts of insulin producing tissue are provided. The number of available human pancreas organs is by and  
25 large the same as the number of kidney donors since the pancreas organs are obtained from the same deceased persons. Another source is pancreas from fetal tissue from abortions, but this source, too, is limited. Therefore, the ability of proliferating the insulin producing  
30 cells by cell cultivation is very important (ref. 1). It is possible to preserve functional islets of Langerhans, isolated from human pancreas, for months under ordinary

tissue culture conditions (see ref. 2 and ref. 3).

However, these known processes involve no increase in the number of beta-cells in cultures of human islets of Langerhans from adults.

5

Even with rat islets of Langerhans, only limited beta-cell division has been observed, which has led to the general assumption that the postnatal division capacity of the beta-cell is poor, while some neoformation and/or division  
10 of beta-cells in vitro seems to occur in the embryonic and very late fetal state (see ref. 4). Only few cases of stimulation of beta-cell division in vitro have been reported, and it has generally been believed that glucose is the most important factor in cell division both  
15 in vivo and in vitro (ref. 4). However, experiments with mice and rats have demonstrated that growth hormone and related hormones, such as prolactin and placental lactogen, may exert a direct stimulating effect on the Langerhans's islets DNA synthesis and insulin production in vitro  
20 (ref. 5). However, this effect diminished as the cultivation period progressed, just as the islet growth in vivo decreases with the age of the animal.

The conventional method of cultivating cells is performed  
25 by depositing the cells on the surface of a solid substrate, e.g. of a plastics material. Such deposit is promoted by the presence of serum, e.g. 10% fetal calf serum, which is therefore widely used in the cultivation of insulin producing cells (ref. 6). Under these conditions, no  
30 effect of growth hormone was observed, either on the DNA synthesis or the insulin production (ref. 7). Increased insulin production is described (ref. 8), and an increased DNA synthesis without an increase in insulin secretion is likewise described (ref. 9 and ref. 10). While  
35 considerable, but time-limited stimulation of both insulin production and DNA synthesis has been demonstrated in the

intact islets (ref. 5), this has so far not been demonstrated in monolayer cultures.

5 The object of the present process is to provide an efficient and rational method of proliferating wholly or partially differentiated beta-cells in large amounts.

10 Another object of the invention is to proliferate cells which produce insulin in considerable amounts and which are useful for implantation in humans.

A further object of the invention is to produce human insulin.

15 The process of the invention, which is characterized by the features stated in the characterizing portion of claim 1, is based on the surprising finding that wholly or partially differentiated beta-cells develop strongly with formation of monolayers by cultivation on a solid  
20 substrate and in contact with a nutrient medium containing both serum and growth hormone in the stated concentration ranges, and when the nutrient medium is repeatedly exchanged during a cultivation period of preferably several weeks.

25

The nutrient medium used in the proliferation of the cells may expediently have a relatively high content of glucose, such as 1/2 - 10 g/l, preferably 1.5 - 5 g/l, with 2 g/l as the optimum value. The content of human serum is  
30 expediently 1/2 - 7%, preferably 1/2 - 3%, with about 2% as the optimum value. Growth hormone of animal or human origin may be replaced by hormones having similar properties, such as prolactin or placental lactogen.

35 The preferred concentration of growth hormone or the hormone having similar properties in the culture medium

is 10 to 1000 ng/ml, such as about 100 ng/ml. A considerable effect may also be obtained, however, at lower concentrations, such as down to about 1 ng/ml. Larger amounts of growth hormone may also be used, such as up to 1000  
5 ng/ml culture medium or more, but, usually, no considerably improved cell formation is obtained at higher concentrations than 200 ng/ml.

The process of the invention permits proliferation of  
10 insulin producing cells of any type, also in the form of host cells into which one or more other gens which are to be expressed in animal or human cells have been introduced. Examples of this are cells in which DNA fragments which code for Factor VIII, growth hormone or interferon  
15 have been introduced.

The process of the invention will be illustrated more fully below by means of some working examples.

#### 20 EXAMPLE 1

Pancrease<sup>1</sup> from 15 three days old rats is excised, treated with collagenase, and the islets are isolated as described in ref. 5. 1000 islets are placed in culture medium RPMI  
25 1640 containing 10% serum from newborn calves, distributed with 100 islets in 5 ml medium in Petri dishes. The dishes stand at 37 °C for 2 days as described in ref. 5. Then the islets are treated with a mixture of EGTA, DNase and trypsin and are aspirated until a cell suspension has been  
30 obtained, as described in ref. 11. The cells are suspended in medium RPMI 1640, and  $10^5$  cells in 5 ml medium are placed in cell cultivation dishes, as described in ref. 9. The dishes stand for 2 days at 37 °C, and the medium is then changed to RPMI 1640 admixed with 2% normal human  
35 serum and 100 ng/ml human growth hormone (Nanormon, Nordisk Gentofte, Denmark). The dishes stand at 37 °C,

and the medium is changed once a week. Insulin is measured by radioimmunoassay, as described in ref. 5.

5 The cells proliferate to colonies, and after 5 months the colonies have spread so that they cover almost the entire dish. They are treated with a mixture of EGTA, DNase and trypsin, and the resulting cell suspension is placed in new dishes with the media RPMI 1640 admixed with 2% normal human serum and 100 ng/ml human growth hormone. Again the  
10 cells proliferate to colonies and spread in the dish. The insulin production increases again gradually.

The results are shown in figure 1 in which curve I refers to the experiment performed in this example. Curve II  
15 refers to a comparative example performed in the same manner, except that no growth hormone was added.

## EXAMPLE 2

20 A cell suspension is produced as described in example 1.  $10^5$  cells suspended in 100  $\mu$ l serum-free medium RPMI 1640 are placed in cell cultivation dishes, and immediately following this are added 5 ml medium RPMI 1640 containing 0.5%, 1%, 2%, 5% and 10% human serum, respectively, as  
25 well as 1  $\mu$ g/ml human growth hormone. The dishes stand at 37 °C, and the medium is changed once a week. The measured insulin amount, released to the medium, is depicted in figure 2 as a function of serum concentration and cultivation time. Maximum insulin production is  
30 obtained after 3 weeks cultivation, as shown, at a serum concentration of 2%.

## REFERENCES

1. Fortune, August 6, 1984, p. 40-43: "Closing in on a Cure for Diabetes" by A.H. Moore.
2. Diabetologia 16, 97-100 (1979): "Preservation of Beta Cell Function in Adult Pancreatic Islets for Several Months in Vitro", by J.H. Nielsen et al.
3. Acta biol. med. germ., vol. 40, p. 55-60 (1981): "Beta-cell function in isolated human pancreatic islets in long-term tissue culture", by J. Høiriis Nielsen.
4. Diabetologia 26: 393-400 (1984): "The life story of the pancreatic B cell", by C. Hellerström.
5. Endocrinology, 110: 600-606 (1982): "Effects of Growth Hormone, Prolactin, and Placental Lactogen on Insulin Content and Release, and Deoxyribonucleic Acid Synthesis in Cultured Pancreatic Islets", by Jens Høiriis Nielsen.
6. US Patent Specification No. 4 439 521, Archer et al.
7. Diabetes 22: 687-693 (1973): "Beta cell replication in rat pancreatic monolayer cultures. Effects of glucose, tolbutamide glucocorticoid, growth hormone and glucasin." by W.L. Chick.
8. Diabetologia 22: 134-137 (1982): "Effects of hypophysectomy and growth hormone on cultured islets of Langerhans of the rat." by J. Pierluissi et al.
9. Cold Spring Harbor Conferences on Cell Proliferation, vol. 9, p. 501-506: "Growth Hormone as a Growth Factor for Normal Pancreatic Islet Cells in Primary Culture", by J. Høiriis Nielsen et al. Published by Cold Spring Harbor Laboratory 1982.
10. Diabetes 32: 307-312 (1983): "Growth hormone stimulates islets B-cell replication in neonatal rat pancreatic monolayer cultures." by A. Rabinovitch et al.



11. Cell Separation: Methods and Selected Applications,  
vol. 2, chapter 7: "Purification of Islets and Cells  
from Islets", by J. Høiriis Nielsen et al.  
Published by Academic Press, 1983.

## Patent Claims

-----

1. A process for proliferation of wholly or partially differentiated beta-cells, comprising suspending islets or islets cultures isolated from human or animal pancreas in a culture medium and contacting them with a solid  
5 substrate until the islets or islet cultures have been deposited on the substrate, and cultivating the islets or islet cultures deposited on the solid substrate in a culture medium under conditions where the beta-cells form monolayers during their growth, c h a r a c t e r i z e d  
10 by culturing in a nutrient medium containing growth hormone or a hormone having similar properties in an amount of 1 - 1000 ng/ml and serum in an amount of 1/2 - 7%, and exchanging the culture medium repeatedly during a cultivation period of several days, preferably  
15 several weeks.


2. A process according to claim 1, c h a r a c t e r - i z e d by performing the cultivation for a period of at least 2 weeks, and exchanging the culture medium  
20 several times, such as once a week.


3. A process according to claims 1 or 2, c h a r a c - t e r i z e d in that the culture medium used for the cultivation of the cells deposited on the solid substrate  
25 contains glucose in an amount of 1/2 - 10 g per litre, preferably 1.5 - 5 g per litre, serum in an amount of 1/2 - 7%, preferably 1/2 - 3%, as well as growth hormone or a hormone having similar properties in an amount of 10 - 1000 ng/ml.

30

4. A process according to any of claims 1-3, c h a r a c t e r i z e d by using human serum and human growth hormone.

Fig. 2





Claim No. 13

if filing date  
publication but  
denying the

ed invention  
insidered to

ed invention  
sp when the  
such docu-  
on sailed

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	DE, A, 2 757 169 (HOECHST AG) 5 July 1979	1
A	GB, A, 2 083 826 (KABUSHIKI KAISHI HAYA- SHIBARA SEIBUTSU) 31 March 1982	1